home / stock / dbvt / dbvt news

DBVT News and Press, DBV Technologies S.A. From 06/09/22

Stock Information
Company Name: DBV Technologies S.A.
Stock Symbol: DBVT
Market: NASDAQ
Website: dbvtechnologies.com
Menu
DBVT DBVT Quote DBVT Short DBVT News DBVT Articles DBVT Message Board
Get DBVT Alerts

News, Short Squeeze, Breakout and More Instantly...
DBVT - TAL, CRDF and VIRX among mid-day movers

Gainers: Power bridge Technologies (PBTS) +177%. Applied UV (AUVI) +50%. Cardiff Oncology (CRDF) +38%. DBV Technologies (DBVT) +28%. View (VIEW) +24%. Viracta Therapeutics (VIRX) +22%. Finger Motion (FNGR) +21%. Scien joy (SJ) +20%. Aero Clean Technologies (AERC) +19%. Akso Health Group (AHG)...
DBVT - DBV Technologies stock extends rally to a second day; co announces $194M financing

DBV Technologies (NASDAQ:DBVT) stock continued its rally on Thursday, adding ~28% to $2.31 in mid-day trading, after an 18.3% gain in the previous session. The company earlier in the day said that it was planning to raise $194M in gross proceeds via a private placement in ...

DBVT - Bluejay, DBV top healthcare gainers; Precision, Blueprint among losers' pack

Gainers: Bluejay Diagnostics BJDX +29%. DBV Technologies DBVT +12%. Arcellx (ACLX) +10%. Immix Biopharma (IMMX) +10%. AbCellera Biologics (ABCL) +8%. Losers: Precision BioSciences (DTIL) -10%. Blueprint Medicines (BPMC) -9%. Hutchmed (China) (HCM)&...

DBVT - DBV Technologies stock dips amid plans to raise $194M via equity financing

DBV Technologies (NASDAQ:DBVT) is planning to raise $194M in gross proceeds via a private investment in public equity (PIPE) financing. The company intends to sell ~32.86M ordinary shares, and pre-funded warrants to buy up to ~28.28M shares. The company said the ordinary shares will be sold a...
DBVT - DBV Technologies Announces Private Placement Financing of $194 Million

Montrouge, France, June 9, 2022 DBV Technologies Announces Private Placement Financing of $194 Million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Global Select Market: DBVT), a clinical-stage biopharmaceutical company, today announced an aggregat...

DBVT - Why DBV Technologies Was a Big Winner on Wednesday

Shares of the unique biotech DBV Technologies (NASDAQ: DBVT) surged nearly 20% higher on Wednesday, far outpacing many peer stocks. That's because the company had some very encouraging news to impart about its key pipeline drug. DBV is developing a patch treatment for peanut all...

DBVT - DBV, Rubius top healthcare gainers; Rigel, Cosmos lead losers' pack

Gainers: DBV Technologies (DBVT) +21%. Rubius Therapeutics (RUBY) +20%. Annovis Bio (ANVS) +17%. LumiraDx (LMDX) +16%. CTI BioPharma (CTIC) +15%. Losers: Rigel Pharmaceuticals (RIGL) -48%. Cosmos (COSM) -13%. Accelerate Diagnostics (AXDX) ...
DBVT - TIGR, GOTU and DTIL among pre market gainers

Cyren (CYRN) +39% on €10M sale of secure email gateway unit. Redbox Entertainment (RDBX) +25%. DBV Technologies (DBVT) +19% phase 3 trial for peanut allergy treatment in toddlers meets main goal. Brenmiller Energy (BNRG) +16%. Energy Focus (EFOI) +15%. Aldeyra Thera...

DBVT - Penny Stocks to Buy With Gains in After Hours? 3 to Watch 

3 Penny Stocks That Climbed in After Hours Trading After a mostly bullish day of trading penny stocks and blue chips, there is a lot for investors to know. Right now, we have to consider the main factors that are at play in the stock market. This includes rising inflation, and more impo...

DBVT - DBV Technologies' phase 3 trial for peanut allergy treatment in toddlers meets main goal

U.S.-listed shares of DBV Technologies (NASDAQ:DBVT) soared nearly 40% to $2.14 in Tuesday aftermarket trading, after the company said its phase 3 trial assessing its Viaskin Peanut for the treatment of peanut allergies in toddlers aged 1 to 3 years met its main goal. Viaskin Peanut...
Previous 10 Next 10